POM-V
Prescription Required
Companion Animal
Cyclavance 100 mg/ml Oral Solution for Dogs and Cats
Active ingredient: Ciclosporin A
Form
Liquid
Species
Cats
Dogs
Manufacturer
Virbac
VMD MA No.
05653/3015
What it's used for
Symptomatic treatment of chronic allergic dermatitis in cats.
Full indications, dosage and side effects ↓The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.
Paying less for Ciclosporin A
-
1
Ask your vet for a written prescription
They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
-
2
Fill it at a registered online retailer
The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.
Done — we'll email you when prices land.
Prescription required
Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.
Clinical information
Cyclavance 100 mg/ml Oral Solution for Dogs and Cats — SPC Details
Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.
Symptomatic treatment of chronic allergic dermatitis in cats.
Before starting treatment, an evaluation of all alternative treatment options should be
made.
Before administration, the body weight of animals has to be accurately determined.
Dogs:
The recommended dose of ciclosporin is 5 mg/kg body weight (0.05 ml of oral
solution per kg BW) and should initially be administered daily. The frequency of
administration should subsequently be reduced depending on the response.
The veterinary medicinal product should initially be given daily until a satisfactory
clinical improvement is seen. This will generally be the case within 4-8 weeks. If no
response is obtained within the first 8 weeks, the treatment should be stopped.
Once the clinical signs of atopic dermatitis are satisfactorily controlled, the veterinary
medicinal product can then be given every second day. The veterinarian should
perform a clinical assessment at regular intervals and adjust the frequency of
administration to the clinical response obtained.
In some cases where the clinical signs are controlled with every second day dosing,
the veterinary surgeon can decide to give the product every 3 to 4 days. The lowest
effective frequency of dosing should be used to maintain the remission of clinical
signs.
Patients should be regularly re-evaluated and alternative treatment options reviewed.
Adjunct treatment (e.g. medicated shampoos, fatty acids) may be considered before
reducing the dosing interval.
The duration of treatment should be adjusted according to treatment response.
Treatment may be stopped when the clinical signs are controlled. Upon recurrence of
clinical signs, treatment should be resumed at daily dosing, and in certain cases
repeated treatment courses may be required.
Dosages for dogs:
At standard dosage of 5mg/kg
Weight
(kg)
Dosage
(ml)
0.10.150.20.250.30.350.40.450.5
Weight
(kg)
Dosage
(ml)
0.550.60.650.70.750.80.850.90.951
Weight
(kg)
Dosage
(ml)
1.051.11.151.21.251.31.351.41.451.5
Weight
(kg)
Dosage
(ml)
1.551.61.651.71.751.81.851.91.952
Weight
(kg)
Dosage
(ml)
2.052.12.152.22.252.32.352.42.452.5
Weight
(kg)
Dosage
(ml)
2.552.62.652.72.752.82.852.92.953
Weight
(kg)
Dosage
(ml)
3.053.13.153.23.253.33.353.43.453.5
Weight
(kg)
Dosage
(ml)
3.553.63.653.73.753.83.853.93.954
PRIMARY PACKAGING TYPE 1
For the 30 and 60 ml bottles, either the 1 ml oral syringe (graduated every 0.05 ml)
or
the 2 ml oral syringe (graduated every 0.1 ml) can be used to achieve the dose
stated above, determined according to bodyweight.
PRIMARY PACKAGING TYPE 2
For the 30 and 50 ml bottles, either the 1 ml oral syringe (graduated every 0.05 ml)
or
the 3 ml oral syringe (graduated every 0.1 ml) can be used to achieve the dose
stated above, determined according to bodyweight.
Cats:
The recommended dose of ciclosporin is 7 mg/kg body weight (0.07 ml of oral
solution per kg) and should initially be administered daily.
The frequency of administration should subsequently be reduced depending on the
response.
The veterinary medicinal product should initially be given daily until a satisfactory
clinical improvement is seen (assessed by intensity of pruritus and lesion severity -
excoriations, miliary dermatitis, eosinophilic plaques and/or self-induced alopecia).
This will generally be the case within 4-8 weeks. Severe prolonged pruritus may
induce a state of anxiety and subsequent excessive grooming behaviour. In such
cases, despite an improvement in pruritus upon administration of the treatment, the
resolution of self-induced alopecia may be delayed.
Once the clinical signs of allergic dermatitis are satisfactorily controlled, the
veterinary medicinal product can then be given every second day. In some cases
where the clinical signs are controlled with every second day dosing, the veterinary
surgeon can decide to give the product every 3 to 4 days. The lowest effective
frequency of dosing should be used to maintain the remission of clinical signs.
Patients should be regularly re-evaluated and alternative treatment options reviewed.
The duration of treatment should be adjusted according to treatment response.
Treatment may be stopped when the clinical signs are controlled. Upon recurrence of
clinical signs, treatment should be resumed at daily dosing, and in certain cases
repeated treatment courses may be required.
The veterinary medicinal product can be given either mixed with food or directly into
the mouth. If given with food, the solution should be mixed with a small amount of
food, preferably after a sufficient period of fasting to ensure complete consumption
by the cat. Should the cat not accept the product mixed with food, it should be given
by inserting the oral syringe directly into the cat’s mouth and delivering the entire
dose. In case the cat only partially consumes the product mixed with food,
administration of the veterinary medicinal product with the oral syringe should be
resumed only the next day. Any uneaten medicated cat food must be disposed of
immediately and the bowl washed thoroughly.
The efficacy and tolerability of this veterinary medicinal product was demonstrated in
clinical studies with a duration of 4.5 months.
Dosage for cats:
As the efficacy and safety of ciclosporin have not been assessed in cats weighing
less than 2.3 kg (see section 4.5), administration of the veterinary medicinal product
to cats weighing less than 2.3 kg should be according to a benefit-risk assessment
by the responsible veterinarian.
At standard dosage of 7 mg/kg
Weight (kg)2.12.93.64.35.05.76.47.1Dosage (ml)0.150.200.250.300.350.400.450.50Weight (kg)7.98.69.310.010.711.412.112.813.614.3Dosage (ml)0.550.600.650.700.750.800.850.900.951.00
PRIMARY PACKAGING TYPE 1
For the 30 and 60 ml bottles, either the 1 ml oral syringe (graduated every 0.05 ml)
or
the 2 ml oral syringe (graduated every 0.1 ml) can be used to achieve the dose
stated above, determined according to bodyweight.
PRIMARY PACKAGING TYPE 2
For the 30 and 50 ml bottles, either the 1 ml oral syringe (graduated every 0.05 ml)
or
the 3 ml oral syringe (graduated every 0.1 ml) can be used to achieve the dose
stated above, determined according to bodyweight.
INSTRUCTIONS FOR USE
Dogs: The veterinary medicinal product should be given at least 2 hours before or
after feeding. Insert the oral syringe directly into the dog’s mouth.
Cats: The product can be given either mixed with food or directly into the mouth in
cats.
PRIMARY PACKAGING TYPE 1
1 Push and turn the child-resistant screw cap to open the bottle.
Always close the bottle with the child-resistant screw cap after use
2 Keep the bottle upright and insert
the oral dosing syringe firmly into the
plastic adapter.
4 Return the bottle to its upright position and remove
the oral dosing syringe by gently twisting it out of the
plastic adapter.
plunger up so that the oral dosing syringe fills with
the product.
Withdraw the dose of medicine prescribed by your
veterinarian.
5 You can now introduce the syringe in the mouth
of your animal and push the medicine out of the
syringe.
Do not rinse or clean the oral dosing syringe
between uses.
Note: If the prescribed dose is more than the
maximum volume marked on the oral dosing
syringe, you will need to reload the syringe to
withdraw the full dose.
Note: For cats, you can also give the product
mixed with food
6 Always close the bottle with the
child-resistant screw cap after use.
To provide a child-resistant closure,
push down on the child-resistant
screw cap as you turn it.
Keep out of the sight and reach of
children
PRIMARY PACKAGING TYPE 2
1 Retrieve the plastic cap and insert firmly the plastic dispenser.
The plastic dispenser should remain in place.
2 Keep the bottle upright and insert
the oral dosing syringe firmly into the
plastic dispenser.
4 You can now introduce the syringe in the mouth of your
animal and push the medicine out of the syringe.
Do not rinse or clean the oral dosing syringe between
uses.
Note: If the prescribed dose is more than the maximum
volume marked on the oral dosing syringe, you will need
to reload the syringe to withdraw the full dose.
Note: For cats, you can also give the product mixed with
food
Keep out of the sight and reach of children
plunger up so that the oral dosing syringe fills with
the product.
Withdraw the dose of medicine prescribed by your
veterinarian.
Return the bottle to its upright position and remove
the oral dosing syringe by gently twisting it out of
the plastic dispenser.
If necessary, the user can wipe the outside of the oral syringe with a dry tissue and
dispose of used tissue immediately.
made.
Before administration, the body weight of animals has to be accurately determined.
Dogs:
The recommended dose of ciclosporin is 5 mg/kg body weight (0.05 ml of oral
solution per kg BW) and should initially be administered daily. The frequency of
administration should subsequently be reduced depending on the response.
The veterinary medicinal product should initially be given daily until a satisfactory
clinical improvement is seen. This will generally be the case within 4-8 weeks. If no
response is obtained within the first 8 weeks, the treatment should be stopped.
Once the clinical signs of atopic dermatitis are satisfactorily controlled, the veterinary
medicinal product can then be given every second day. The veterinarian should
perform a clinical assessment at regular intervals and adjust the frequency of
administration to the clinical response obtained.
In some cases where the clinical signs are controlled with every second day dosing,
the veterinary surgeon can decide to give the product every 3 to 4 days. The lowest
effective frequency of dosing should be used to maintain the remission of clinical
signs.
Patients should be regularly re-evaluated and alternative treatment options reviewed.
Adjunct treatment (e.g. medicated shampoos, fatty acids) may be considered before
reducing the dosing interval.
The duration of treatment should be adjusted according to treatment response.
Treatment may be stopped when the clinical signs are controlled. Upon recurrence of
clinical signs, treatment should be resumed at daily dosing, and in certain cases
repeated treatment courses may be required.
Dosages for dogs:
At standard dosage of 5mg/kg
Weight
(kg)
Dosage
(ml)
0.10.150.20.250.30.350.40.450.5
Weight
(kg)
Dosage
(ml)
0.550.60.650.70.750.80.850.90.951
Weight
(kg)
Dosage
(ml)
1.051.11.151.21.251.31.351.41.451.5
Weight
(kg)
Dosage
(ml)
1.551.61.651.71.751.81.851.91.952
Weight
(kg)
Dosage
(ml)
2.052.12.152.22.252.32.352.42.452.5
Weight
(kg)
Dosage
(ml)
2.552.62.652.72.752.82.852.92.953
Weight
(kg)
Dosage
(ml)
3.053.13.153.23.253.33.353.43.453.5
Weight
(kg)
Dosage
(ml)
3.553.63.653.73.753.83.853.93.954
PRIMARY PACKAGING TYPE 1
For the 30 and 60 ml bottles, either the 1 ml oral syringe (graduated every 0.05 ml)
or
the 2 ml oral syringe (graduated every 0.1 ml) can be used to achieve the dose
stated above, determined according to bodyweight.
PRIMARY PACKAGING TYPE 2
For the 30 and 50 ml bottles, either the 1 ml oral syringe (graduated every 0.05 ml)
or
the 3 ml oral syringe (graduated every 0.1 ml) can be used to achieve the dose
stated above, determined according to bodyweight.
Cats:
The recommended dose of ciclosporin is 7 mg/kg body weight (0.07 ml of oral
solution per kg) and should initially be administered daily.
The frequency of administration should subsequently be reduced depending on the
response.
The veterinary medicinal product should initially be given daily until a satisfactory
clinical improvement is seen (assessed by intensity of pruritus and lesion severity -
excoriations, miliary dermatitis, eosinophilic plaques and/or self-induced alopecia).
This will generally be the case within 4-8 weeks. Severe prolonged pruritus may
induce a state of anxiety and subsequent excessive grooming behaviour. In such
cases, despite an improvement in pruritus upon administration of the treatment, the
resolution of self-induced alopecia may be delayed.
Once the clinical signs of allergic dermatitis are satisfactorily controlled, the
veterinary medicinal product can then be given every second day. In some cases
where the clinical signs are controlled with every second day dosing, the veterinary
surgeon can decide to give the product every 3 to 4 days. The lowest effective
frequency of dosing should be used to maintain the remission of clinical signs.
Patients should be regularly re-evaluated and alternative treatment options reviewed.
The duration of treatment should be adjusted according to treatment response.
Treatment may be stopped when the clinical signs are controlled. Upon recurrence of
clinical signs, treatment should be resumed at daily dosing, and in certain cases
repeated treatment courses may be required.
The veterinary medicinal product can be given either mixed with food or directly into
the mouth. If given with food, the solution should be mixed with a small amount of
food, preferably after a sufficient period of fasting to ensure complete consumption
by the cat. Should the cat not accept the product mixed with food, it should be given
by inserting the oral syringe directly into the cat’s mouth and delivering the entire
dose. In case the cat only partially consumes the product mixed with food,
administration of the veterinary medicinal product with the oral syringe should be
resumed only the next day. Any uneaten medicated cat food must be disposed of
immediately and the bowl washed thoroughly.
The efficacy and tolerability of this veterinary medicinal product was demonstrated in
clinical studies with a duration of 4.5 months.
Dosage for cats:
As the efficacy and safety of ciclosporin have not been assessed in cats weighing
less than 2.3 kg (see section 4.5), administration of the veterinary medicinal product
to cats weighing less than 2.3 kg should be according to a benefit-risk assessment
by the responsible veterinarian.
At standard dosage of 7 mg/kg
Weight (kg)2.12.93.64.35.05.76.47.1Dosage (ml)0.150.200.250.300.350.400.450.50Weight (kg)7.98.69.310.010.711.412.112.813.614.3Dosage (ml)0.550.600.650.700.750.800.850.900.951.00
PRIMARY PACKAGING TYPE 1
For the 30 and 60 ml bottles, either the 1 ml oral syringe (graduated every 0.05 ml)
or
the 2 ml oral syringe (graduated every 0.1 ml) can be used to achieve the dose
stated above, determined according to bodyweight.
PRIMARY PACKAGING TYPE 2
For the 30 and 50 ml bottles, either the 1 ml oral syringe (graduated every 0.05 ml)
or
the 3 ml oral syringe (graduated every 0.1 ml) can be used to achieve the dose
stated above, determined according to bodyweight.
INSTRUCTIONS FOR USE
Dogs: The veterinary medicinal product should be given at least 2 hours before or
after feeding. Insert the oral syringe directly into the dog’s mouth.
Cats: The product can be given either mixed with food or directly into the mouth in
cats.
PRIMARY PACKAGING TYPE 1
1 Push and turn the child-resistant screw cap to open the bottle.
Always close the bottle with the child-resistant screw cap after use
2 Keep the bottle upright and insert
the oral dosing syringe firmly into the
plastic adapter.
4 Return the bottle to its upright position and remove
the oral dosing syringe by gently twisting it out of the
plastic adapter.
plunger up so that the oral dosing syringe fills with
the product.
Withdraw the dose of medicine prescribed by your
veterinarian.
5 You can now introduce the syringe in the mouth
of your animal and push the medicine out of the
syringe.
Do not rinse or clean the oral dosing syringe
between uses.
Note: If the prescribed dose is more than the
maximum volume marked on the oral dosing
syringe, you will need to reload the syringe to
withdraw the full dose.
Note: For cats, you can also give the product
mixed with food
6 Always close the bottle with the
child-resistant screw cap after use.
To provide a child-resistant closure,
push down on the child-resistant
screw cap as you turn it.
Keep out of the sight and reach of
children
PRIMARY PACKAGING TYPE 2
1 Retrieve the plastic cap and insert firmly the plastic dispenser.
The plastic dispenser should remain in place.
2 Keep the bottle upright and insert
the oral dosing syringe firmly into the
plastic dispenser.
4 You can now introduce the syringe in the mouth of your
animal and push the medicine out of the syringe.
Do not rinse or clean the oral dosing syringe between
uses.
Note: If the prescribed dose is more than the maximum
volume marked on the oral dosing syringe, you will need
to reload the syringe to withdraw the full dose.
Note: For cats, you can also give the product mixed with
food
Keep out of the sight and reach of children
plunger up so that the oral dosing syringe fills with
the product.
Withdraw the dose of medicine prescribed by your
veterinarian.
Return the bottle to its upright position and remove
the oral dosing syringe by gently twisting it out of
the plastic dispenser.
If necessary, the user can wipe the outside of the oral syringe with a dry tissue and
dispose of used tissue immediately.
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
Do not use in cases with a history of malignant disorders or progressive malignant
disorders.
Do not vaccinate with a live vaccine during treatment or within a two-week interval
before or after treatment (see also sections 3.5 “Special precautions for use” and 3.8
“Interaction with other medicinal products and other forms of interaction”).
Do not use in dogs less than six months of age or less than 2 kg in weight.
Do not use in cats infected with Feline Leukemia Virus (FeLV) or Feline
Immunodeficiency Virus (FIV).
excipients.
Do not use in cases with a history of malignant disorders or progressive malignant
disorders.
Do not vaccinate with a live vaccine during treatment or within a two-week interval
before or after treatment (see also sections 3.5 “Special precautions for use” and 3.8
“Interaction with other medicinal products and other forms of interaction”).
Do not use in dogs less than six months of age or less than 2 kg in weight.
Do not use in cats infected with Feline Leukemia Virus (FeLV) or Feline
Immunodeficiency Virus (FIV).
Regarding malignancy, please see sections 3.3 “Contraindications” and 3.5 “Special
precautions for use”.
Dogs:
Uncommon
(1 to 10 animals
/ 1,000 animals
treated):
Digestive tract disorders (e.g. vomiting, mucous
stool, loose stool and diarrhoea)
2,4
,
Lethargy
, Anorexia
Hyperactivity
,
Gingival hyperplasia
1,4
,
Skin reactions (e.g. verruciform lesion or hair
change)
,
Pinnal reddening and Pinnal oedema
,
Muscle weakness or Muscle cramps
Very rare
(<1 animal / 10,000
animals treated,
including isolated
reports):
Diabetes mellitus
3Undetermined
Frequency
Hypersalivation
2,4
Mild and moderate.
Mild and transient and generally do not require the cessation of the treatment.
Especially in West Highland White Terriers.
Generally resolve spontaneously after treatment is stopped.
Cats:
Very common
(>1 animal / 10
animals treated):
Digestive tract disorders (e.g. vomiting and
diarrhoea), Weight loss
Common
(1 to 10 animals /
100 animals treated):
Increased appetite,
Lethargy, Anorexia, Hypersalivation,
Hyperactivity, Polydipsia, Gingival hyperplasia
and Lymphopaenia
1
Generally mild and transient and do not require the cessation of the treatment.
Generally resolve spontaneously after treatment is stopped or following a decrease
in the dosing frequency.
Side effects may be severe in individual animals.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a
veterinarian, to either the marketing authorisation holder or its local representative
or the national competent authority via the national reporting system. See the
package leaflet for respective contact details.
precautions for use”.
Dogs:
Uncommon
(1 to 10 animals
/ 1,000 animals
treated):
Digestive tract disorders (e.g. vomiting, mucous
stool, loose stool and diarrhoea)
2,4
,
Lethargy
, Anorexia
Hyperactivity
,
Gingival hyperplasia
1,4
,
Skin reactions (e.g. verruciform lesion or hair
change)
,
Pinnal reddening and Pinnal oedema
,
Muscle weakness or Muscle cramps
Very rare
(<1 animal / 10,000
animals treated,
including isolated
reports):
Diabetes mellitus
3Undetermined
Frequency
Hypersalivation
2,4
Mild and moderate.
Mild and transient and generally do not require the cessation of the treatment.
Especially in West Highland White Terriers.
Generally resolve spontaneously after treatment is stopped.
Cats:
Very common
(>1 animal / 10
animals treated):
Digestive tract disorders (e.g. vomiting and
diarrhoea), Weight loss
Common
(1 to 10 animals /
100 animals treated):
Increased appetite,
Lethargy, Anorexia, Hypersalivation,
Hyperactivity, Polydipsia, Gingival hyperplasia
and Lymphopaenia
1
Generally mild and transient and do not require the cessation of the treatment.
Generally resolve spontaneously after treatment is stopped or following a decrease
in the dosing frequency.
Side effects may be severe in individual animals.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a
veterinarian, to either the marketing authorisation holder or its local representative
or the national competent authority via the national reporting system. See the
package leaflet for respective contact details.
Consideration should be given to the use of other measures and/or treatments to
control moderate to severe pruritus when initiating therapy with ciclosporin.
Special precautions for safe use in the target species:
Clinical signs of atopic dermatitis in dogs and allergic dermatitis in cats such as
pruritus and skin inflammation are not specific for these diseases. Other causes of
dermatitis such as ectoparasitic infestations, other allergies which cause
dermatological signs (e.g. flea allergic dermatitis or food allergy) or bacterial and
fungal infections should be ruled out before treatment is started. It is good practice to
treat flea infestations before and during treatment of atopic or allergic dermatitis.
A complete clinical examination should be performed prior to treatment. While
ciclosporin does not induce tumours, it does inhibit T-lymphocytes and therefore
treatment with ciclosporin may lead to an increased incidence of clinically apparent
malignancy due to the decrease in antitumour immune response. The potentially
increased risk of tumour progression must be weighed against the clinical benefit. If
lymphadenopathy is observed in animals being treated with ciclosporin, further
clinical investigations are recommended and treatment discontinued if necessary.
It is recommended to clear bacterial and fungal infections before administering the
veterinary medicinal product. However, infections occurring during treatment are not
necessarily a reason for drug withdrawal, unless the infection is severe.
In laboratory animals, ciclosporin is liable to affect the circulating levels of insulin and
to cause an increase in glycaemia. If signs of diabetes mellitus are observed
following the use of the product, e.g. polyuria, polydipsia, the dose should be tapered
or discontinued and veterinary care sought.'
In the presence of suggestive signs of diabetes mellitus, the effect of treatment on
glycaemia must be monitored. The use of ciclosporin is not recommended in diabetic
animals.
Particular attention must be paid to vaccination. Treatment with the veterinary
medicinal product may interfere with vaccination efficacy. In the case of inactivated
vaccines, it is not recommended to vaccinate during treatment or within a two-week
interval before or after administration of the veterinary medicinal product. For live
vaccines see also section 3.3 “Contraindications”.
It is not recommended to use other immunosuppressive agents concomitantly.
Dogs:
Closely monitor creatinine levels with severe renal insufficiency.
Cats:
Allergic dermatitis in cats can have various manifestations, including eosinophilic
plaques, head and neck excoriation, symmetrical alopecia and/or miliary dermatitis.
The immune status of the cats to FeLV and FIV infections should be assessed
before treatment.
Cats that are seronegative for T. gondii may be at risk of developing clinical
toxoplasmosis if they become infected while under treatment. In rare cases this can
be fatal. Potential exposure of seronegative cats or cats suspected to be
seronegative to Toxoplasma should therefore be minimised (e.g. keep indoors, avoid
raw meat or scavenging). However, in a controlled laboratory study, treatment with
ciclosporin did not reactivate oocyst shedding in cats previously exposed to T. gondii.
In cases of clinical toxoplasmosis or other serious systemic illness, stop treatment
with ciclosporin and initiate appropriate therapy.
Clinical studies in cats have shown that decreased appetite and weight loss may
occur during ciclosporin treatment. Monitoring of body weight is recommended.
Significant reduction in body weight may result in hepatic lipidosis. If persistent,
progressive weight loss occurs during treatment it is recommended to discontinue
treatment until the cause has been identified.
The efficacy and safety of ciclosporin has neither been assessed in cats less than 6
months of age nor weighing less than 2.3 kg.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Accidental ingestion of this veterinary medicinal product may lead to nausea and/or
vomiting. To avoid accidental ingestion, the veterinary medicinal product must be
used and kept out of reach of children. Do not leave unattended filled oral syringes in
the presence of children. Any uneaten medicated cat food must be disposed of
immediately and the bowl washed thoroughly. In case of accidental ingestion,
particularly by a child, seek medical advice immediately and show the package
leaflet or the label to the physician. Ciclosporin can trigger hypersensitivity (allergic)
reactions. People with known hypersensitivity to ciclosporin should avoid contact with
the veterinary medicinal product. This product may cause irritation in case of eye
contact. Avoid contact with eyes. In case of contact, rinse thoroughly with clean
water. Wash hands and any exposed skin after use.
Special precautions for the protection of the environment:
Not applicable.
control moderate to severe pruritus when initiating therapy with ciclosporin.
Special precautions for safe use in the target species:
Clinical signs of atopic dermatitis in dogs and allergic dermatitis in cats such as
pruritus and skin inflammation are not specific for these diseases. Other causes of
dermatitis such as ectoparasitic infestations, other allergies which cause
dermatological signs (e.g. flea allergic dermatitis or food allergy) or bacterial and
fungal infections should be ruled out before treatment is started. It is good practice to
treat flea infestations before and during treatment of atopic or allergic dermatitis.
A complete clinical examination should be performed prior to treatment. While
ciclosporin does not induce tumours, it does inhibit T-lymphocytes and therefore
treatment with ciclosporin may lead to an increased incidence of clinically apparent
malignancy due to the decrease in antitumour immune response. The potentially
increased risk of tumour progression must be weighed against the clinical benefit. If
lymphadenopathy is observed in animals being treated with ciclosporin, further
clinical investigations are recommended and treatment discontinued if necessary.
It is recommended to clear bacterial and fungal infections before administering the
veterinary medicinal product. However, infections occurring during treatment are not
necessarily a reason for drug withdrawal, unless the infection is severe.
In laboratory animals, ciclosporin is liable to affect the circulating levels of insulin and
to cause an increase in glycaemia. If signs of diabetes mellitus are observed
following the use of the product, e.g. polyuria, polydipsia, the dose should be tapered
or discontinued and veterinary care sought.'
In the presence of suggestive signs of diabetes mellitus, the effect of treatment on
glycaemia must be monitored. The use of ciclosporin is not recommended in diabetic
animals.
Particular attention must be paid to vaccination. Treatment with the veterinary
medicinal product may interfere with vaccination efficacy. In the case of inactivated
vaccines, it is not recommended to vaccinate during treatment or within a two-week
interval before or after administration of the veterinary medicinal product. For live
vaccines see also section 3.3 “Contraindications”.
It is not recommended to use other immunosuppressive agents concomitantly.
Dogs:
Closely monitor creatinine levels with severe renal insufficiency.
Cats:
Allergic dermatitis in cats can have various manifestations, including eosinophilic
plaques, head and neck excoriation, symmetrical alopecia and/or miliary dermatitis.
The immune status of the cats to FeLV and FIV infections should be assessed
before treatment.
Cats that are seronegative for T. gondii may be at risk of developing clinical
toxoplasmosis if they become infected while under treatment. In rare cases this can
be fatal. Potential exposure of seronegative cats or cats suspected to be
seronegative to Toxoplasma should therefore be minimised (e.g. keep indoors, avoid
raw meat or scavenging). However, in a controlled laboratory study, treatment with
ciclosporin did not reactivate oocyst shedding in cats previously exposed to T. gondii.
In cases of clinical toxoplasmosis or other serious systemic illness, stop treatment
with ciclosporin and initiate appropriate therapy.
Clinical studies in cats have shown that decreased appetite and weight loss may
occur during ciclosporin treatment. Monitoring of body weight is recommended.
Significant reduction in body weight may result in hepatic lipidosis. If persistent,
progressive weight loss occurs during treatment it is recommended to discontinue
treatment until the cause has been identified.
The efficacy and safety of ciclosporin has neither been assessed in cats less than 6
months of age nor weighing less than 2.3 kg.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Accidental ingestion of this veterinary medicinal product may lead to nausea and/or
vomiting. To avoid accidental ingestion, the veterinary medicinal product must be
used and kept out of reach of children. Do not leave unattended filled oral syringes in
the presence of children. Any uneaten medicated cat food must be disposed of
immediately and the bowl washed thoroughly. In case of accidental ingestion,
particularly by a child, seek medical advice immediately and show the package
leaflet or the label to the physician. Ciclosporin can trigger hypersensitivity (allergic)
reactions. People with known hypersensitivity to ciclosporin should avoid contact with
the veterinary medicinal product. This product may cause irritation in case of eye
contact. Avoid contact with eyes. In case of contact, rinse thoroughly with clean
water. Wash hands and any exposed skin after use.
Special precautions for the protection of the environment:
Not applicable.
Various substances are known to competitively inhibit or induce the enzymes
involved in the metabolism of ciclosporin, in particular cytochrome P450 (CYP3A4).
In certain clinically justified cases, an adjustment of the dosage of the veterinary
medicinal product may be required.
The compound class of azoles (e.g. ketoconazole) is known to increase the blood
concentration of ciclosporin in dogs and cats, which is considered to be clinically
relevant. Ketoconazole at 5-10 mg/kg is known to increase the blood concentration
of ciclosporin in dogs up to five-fold. During concomitant use of ketoconazole and
ciclosporin the veterinarian should consider as a practical measure to double the
treatment interval if the dog is on a daily treatment regime. Macrolides such as
erythromycin may increase the plasma levels of ciclosporin up to twofold. Certain
inducers of cytochrome P450, anticonvulsants and antibiotics (e.g. trimethoprim/
sulfadimidine) may lower the plasma concentration of ciclosporin.
Ciclosporin is a substrate and an inhibitor of the MDR1 P-glycoprotein transporter.
Therefore, the co-administration of ciclosporin with P-glycoprotein substrates such as
macrocyclic lactones, e.g. ivermectin and milbemycin, could decrease the efflux of
such drugs from blood-brain barrier cells, potentially resulting in signs of CNS
toxicity.
Ciclosporin can increase the nephrotoxicity of aminoglycoside antibiotics and
trimethoprim. The concomitant use of ciclosporin is not recommended with these
active ingredients.
Particular attention must be paid to vaccination (see section 3.3 “Contraindications”
and 3.5 “Special precautions for use”) and to concomitantuse of other
immunosuppressive agents (see section 3.5 “Special precautions for use”).
involved in the metabolism of ciclosporin, in particular cytochrome P450 (CYP3A4).
In certain clinically justified cases, an adjustment of the dosage of the veterinary
medicinal product may be required.
The compound class of azoles (e.g. ketoconazole) is known to increase the blood
concentration of ciclosporin in dogs and cats, which is considered to be clinically
relevant. Ketoconazole at 5-10 mg/kg is known to increase the blood concentration
of ciclosporin in dogs up to five-fold. During concomitant use of ketoconazole and
ciclosporin the veterinarian should consider as a practical measure to double the
treatment interval if the dog is on a daily treatment regime. Macrolides such as
erythromycin may increase the plasma levels of ciclosporin up to twofold. Certain
inducers of cytochrome P450, anticonvulsants and antibiotics (e.g. trimethoprim/
sulfadimidine) may lower the plasma concentration of ciclosporin.
Ciclosporin is a substrate and an inhibitor of the MDR1 P-glycoprotein transporter.
Therefore, the co-administration of ciclosporin with P-glycoprotein substrates such as
macrocyclic lactones, e.g. ivermectin and milbemycin, could decrease the efflux of
such drugs from blood-brain barrier cells, potentially resulting in signs of CNS
toxicity.
Ciclosporin can increase the nephrotoxicity of aminoglycoside antibiotics and
trimethoprim. The concomitant use of ciclosporin is not recommended with these
active ingredients.
Particular attention must be paid to vaccination (see section 3.3 “Contraindications”
and 3.5 “Special precautions for use”) and to concomitantuse of other
immunosuppressive agents (see section 3.5 “Special precautions for use”).
Keep the bottle in the outer carton.
Do not refrigerate.
A jelly-like formation may occur below 15°C which is however reversible at
temperatures up to 25°C without affecting the quality of the product.
After first opening: Do not store above 25C.
Do not refrigerate.
A jelly-like formation may occur below 15°C which is however reversible at
temperatures up to 25°C without affecting the quality of the product.
After first opening: Do not store above 25C.
Not applicable.
This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.
Medication costs adding up?
Pet insurance can cover prescription medications. Find the right policy for your pet.
Related Conditions
Same active ingredient
Other Products Containing Ciclosporin A
These products share the same active ingredient and may be suitable alternatives. Always consult your vet.
Atopica 10 mg Soft Capsules for Dogs
POM-VElanco GmbH
capsule
Dogs
Atopica 10 mg Soft Capsules for Dogs
POM-VElanco GmbH
capsule
Dogs
Atopica 100 mg Soft Capsules for Dogs
POM-VElanco GmbH
capsule
Dogs
Atopica 100 mg Soft Capsules for Dogs
POM-VElanco GmbH
capsule
Dogs
Atopica 100 mg/ml Oral Solution for Cats and Dogs
POM-VElanco GmbH
liquid
Cats
Dogs
Atopica 100 mg/ml Oral Solution for Cats and Dogs
POM-VElanco GmbH
liquid
Cats
Dogs
Alternative options to consider
Retailers we earn a commission from. It costs you nothing and never changes what we show.
The Pharm Pet Co.
The Pharm Pet Co. — Pet Pharmacy
UK online pet pharmacy. Flea, worm, prescription medications, supplements and pet food. Save vs vet prices.
Save up to 50%
Shop now
Pharmacy2U
Pet Care at Pharmacy2U
The UK's largest online pharmacy. Pet wormers, flea treatments, dental and joint care. Free delivery on orders over £30.
Free delivery £30+
Shop now
Petlibro
Petlibro Automatic Feeder
Smart automatic pet feeder with app control. Schedule meals, portion control, and feeding history.
From £49.99
Shop now
We may earn a small commission if you purchase through these links, at no extra cost to you.
Also in anti-inflammatory
Related Medications
Adequan 100 mg/ml Solution for Injection
POM-VPolysulphated Glycosaminoglycan
injection
Rx
Horses
Alcort 0.584 mg/ml Cutaneous Spray, Solution
POM-VHydrocortisone Aceponate
spray
Rx
Dogs
Allevinix 50 mg/ml Solution for Injection for Cattle, Horses, Pigs
POM-VFlunixin
injection
Rx
Cattle
Horses
Allevinix 50 mg/ml Solution for Injection for Cattle, Horses, Pigs
POM-VFlunixin
injection
Rx
Cattle
Horses
Anarthron 100 mg/mL Solution for Injection for Dogs
POM-VPentosan Polysulphate Sodium
injection
Rx
Dogs
Anarthron 100 mg/mL Solution for Injection for Dogs
POM-VPentosan Polysulphate Sodium
injection
Rx
Dogs
Find cheaper vets near you
Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.